// App-Quantinova.ai

E064 : The relationship between lipid profile changes and inflammation across the Phase 3 sarilumab rheumatoid arthritis (RA) development programme

Researchers

Presenter

  • Christina Charles-Schoeman

Principal Investigators

  • Gregory St John

  • Henry Leher

  • Toshio Kimura

  • Hubert van Hoogstraten

  • Michael Nurmohamed

  • Miguel A Gonzlez-Gay

  • Elaine Wilson

  • Edward C Keystone

Medical Centers

  • Ronald Reagan UCLA Medical Center, Los Angeles, CA

  • Medical Analytics, Medical Affairs, Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA

  • Medical Analytics, Medical Affairs, Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA

  • Medical Affairs, Sanofi, Bridgewater, NJ, USA

  • Rheumatology, VU University Medical Center, Amsterdam

  • Pathology, University Hospital Marques de Valdecilla, Satander, SPAIN

  • Rheumatology, Sanofi Genzyme, Oxford, UNITED KINGDOM

  • Rheumatology, University of Toronto and Mount Sinai Hospital, Toronto, ON, CANADA

Locations

  • United States

  • Netherlands

  • Spain

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

  • Serum amyloid A

Drug/Treatment

  • Methotrexate

  • Adalimumab

  • Sarilumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT01061736

  • NCT01709578

  • NCT02332590

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved